Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07323095
PHASE2

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Sponsor: Atom Therapeutics Co., Ltd

View on ClinicalTrials.gov

Summary

This is a phase 2, international, multicenter, randomized, double blind, parallel group trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 28

Official title: A Phase 2, International, Multicenter, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2026-02-01

Completion Date

2028-01-31

Last Updated

2026-01-07

Healthy Volunteers

No

Interventions

DRUG

ABP-671 plus febuxostat Group 1

ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)

DRUG

ABP-671 plus febuxostat Group 2

ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)

DRUG

ABP-671 Group

ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)

Locations (8)

Genesis Research services

Newcastle, New South Wales, Australia

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, China

Peking University First Hospital

Beijing, Beijing Municipality, China

Xuanwu Hospital Capital Medical University

Beijing, Beijing Municipality, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China